EU plans for greater Health Technology Assessment
Our expert's opinion
"HTA harmonisation across Europe could really reduce the time to market for both Pharma and MedDev companies. The question, however, is if payers and health authorities, in such a heterogeneous health environment as Europe, really can converge on a single frame to assess Health Technologies? The 2020 goal for harmonisation might be too ambitious in my opinion but it is great to see the process moving forward."
- Jorge Alfonso, Associate Consultant
Is Europe ready for a single health technology assessment?
After years of preparation, the EU unveiled plans for greater Health Technology Assessment harmonisation this week – and put the potential benefits for life sciences centre stage
The vision of medicines and medical devices moving towards a single EU health technology appraisal took one step closer to reality this week – and the pharma industry welcomed it.
While the European Union (EU) has had a single centralised approval for new medicines since 2004, health technology assessment (HTA) has remained a matter for member states, reflecting its use in deciding national pricing and reimbursement and market access decisions.
There is indeed great variation in how countries appraise medicines – France is very different to Greece or Romania, for example. But while member states and other stakeholders once resisted convergence on HTA, opinions have shifted in recent years.
This week the European Commission put forward detailed plans to make it a reality in EU law by 2020 – though, while many patient groups, healthcare providers and academics want to go all the way and have a single EU system, it seems health ministries and payers advocate a more limited move to greater harmonisation.
Seeking to find middle ground on these views, the European Commission has put forward a proposal which it says will “boost co-operation amongst EU member states for assessing health technology”. It believes this will create greater transparency, which will, in turn, empower patients by ensuring they have access to information on the added clinical value of new technologies that could potentially benefit them.
The Commission says national authorities will be able to formulate policies for their health systems based on more robust evidence.
Finally, it also claims that harmonised assessments could lead to effective, innovative health tools reaching patients faster – and that, naturally, is attractive to pharma and medical device companies.
Such a system could also potentially reduce the huge effort which currently goes into navigating each EU member state’s HTA.
Jyrki Katainen is vice president of the European Commission. He launched the proposals this week, and highlighted the potential benefits to the life sciences industry.
“Reinforcing Health Technology Assessment co-operation at EU level boosts innovation and improves competitiveness of the medical industry,” said Katainen.
“The healthcare sector is a crucial part of our economy; it accounts for approximately 10% of the EU’s GDP. We are proposing a regulatory framework that will bring benefits to patients all over Europe, whilst encouraging innovation, helping the take-up of high-quality medtech innovations and improving the sustainability of health systems across the EU.”
European Commissioner for Health and Food Safety, Vytenis Andriukaitis, added: “Today, the Commission has put the wheels in motion for better quality, innovative healthcare for the benefit of patients, especially those with unmet medical needs. I also expect this initiative to result in a more efficient use of resources by member states through the pooling of resources and exchanges of expertise, thereby avoiding duplications in the assessment of the identical products.”
Europe’s pharma association EFPIA says the proposals are “a positive, collective step forward in supporting access to new treatments for patients across Europe”.
EFPIA Director General Nathalie Moll said, “Access to innovative health technologies for EU patients is a shared goal. Our healthcare systems are facing some unprecedented challenges from an ageing population and the increasing prevalence of diseases such as diabetes, cancer and dementia.”
The association picked out three key areas of proposed greater collaboration which it welcomed: joint clinical assessments, joint scientific consultation or “early dialogue” and harmonised horizon scanning.
“Like with any substantial policy development, there will be areas of implementation that require further examination and discussion,” Moll concluded.
“At EFPIA, we look forward to continuing the dialogue with all stakeholders, including patients, healthcare professionals, representatives from member states and EU institutions to ensure that the proposals help us achieve the shared goal of improving the availability of innovative health solutions to patients across Europe.”
The European Commission put forward five different scenarios for collaboration on HTA after 2020, ranging from 1 – basically the status quo, to 5, a full-blooded, mandatory harmonisation of processes across the EU.
Quite how far towards ‘5’ Europe will go in a final agreement is anyone’s guess at the moment, as EU decision making always requires compromise and horse-trading.
While there is enthusiasm for the concept in pharma, there is also caution: in its submission to a broad consultation last year, Roche said any HTA co-operation after 2020 should be voluntary for both companies and member states in a transition period, until the system had proved itself. [Read pharma responses to the consultation here]
Brexit and beyond
For the UK pharmaceutical industry, facing the huge regulatory and trade problems posed by Brexit, the plans represent further potential benefits of EU membership which it looks likely to miss out on. This would be particularly ironic as NICE is seen as the world’s most advanced HTA body.
However, it is the Netherlands which has taken a lead in co-ordinating European HTA dialogue so far, via EUnetHTA. This is chaired by Wim Goettsch, an executive at the Zorginstituut Nederland, the country’s HTA body.
This conjures up the interesting prospect of a pan-European HTA body being located in the Netherlands, close to the European Medicines Agency, once it relocates to Amsterdam from London.
Of course it’s too early to speculate on such an eventuality, but there’s little doubt that Europe will move towards greater harmonisation on HTA – and pharma is convinced, like other stakeholders, that the likely benefits will outweigh any potential downsides.
Source: Pharma Phorum
Other insights in Pharmaceutical Affairs
Read our insight
Working as a pharma professional at Strand: what is it like?